This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Recent Price Trend in Zealand Pharma AS (ZLDPF) is Your Friend, Here's Why
by Zacks Equity Research
Zealand Pharma AS (ZLDPF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Zealand Pharma AS (ZLDPF) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Zealand Pharma AS (ZLDPF) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Here's Why Momentum in Zealand Pharma AS (ZLDPF) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Zealand Pharma AS (ZLDPF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of 0% and 0.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clearside Biomedical (CLSD) delivered earnings and revenue surprises of 28.57% and 64.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 10.20% and 30.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's What Could Help Zealand Pharma AS (ZLDPF) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Zealand Pharma AS (ZLDPF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 11.6% Jump Turn into More Strength?
by Zacks Equity Research
Zealand Pharma AS (ZLDPF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Computer Programs and Systems (CPSI) Q3 Earnings Beat Estimates
by Zacks Equity Research
Computer Programs and Systems (CPSI) delivered earnings and revenue surprises of 12.50% and 2.65%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lumos (LUMO) delivered earnings and revenue surprises of -2.83% and 6.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Novavax (NVAX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of 146.77% and 64.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 14.89% and 0.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zealand Pharma A/S (ZLDPF) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Zealand Pharma A/S (ZLDPF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Recent Price Trend in Zealand Pharma A/S (ZLDPF) is Your Friend, Here's Why
by Zacks Equity Research
Zealand Pharma A/S (ZLDPF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Zealand Pharma A/S (ZLDPF) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Zealand Pharma A/S (ZLDPF) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.